thalidomide has been researched along with Cockayne-Touraine Disease in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Rani, S | 1 |
Gupta, A | 1 |
Bhardwaj, M | 1 |
Ozanic Bulic, S | 1 |
Fassihi, H | 1 |
Mellerio, JE | 1 |
McGrath, JA | 1 |
Atherton, DJ | 1 |
2 other studies available for thalidomide and Cockayne-Touraine Disease
Article | Year |
---|---|
Epidermolysis bullosa pruriginosa: A rare entity which responded well to thalidomide.
Topics: Adult; Biopsy; Epidermolysis Bullosa Dystrophica; Humans; Immunosuppressive Agents; Male; Rare Disea | 2019 |
Thalidomide in the management of epidermolysis bullosa pruriginosa.
Topics: Adolescent; Epidermolysis Bullosa Dystrophica; Female; Humans; Immunosuppressive Agents; Point Mutat | 2005 |